Inadequately controlled while receiving triple inhaled therapy1,a:

Breathlessness, cough, mucus,
and dyspnea

Exacerbations1:

Experienced moderate or severe exacerbations in previous year

Elevated blood EOS (≥300
cells/μL)1:

Evidence of type 2 inflammation

An elevated blood EOS level is recognized by the 2025 GOLD Report as a clinically useful
biomarker for identifying COPD with type 2 inflammation2

aTripled inhaled therapy is LAMA+LABA+ICS.1,2

COPD, chronic obstructive pulmonary disease; EOS, eosinophils; GOLD, Global Initiative for Chronic Obstructive Lung Disease; ICS, inhaled corticosteroid; LABA, long-acting
beta agonist; LAMA, long-acting muscarinic antagonist.

Help appropriate patients benefit from the only
biologic approved in COPD

Discover the results

Get more information on the
clinical trials

Explore the full study
designs

FREQUENTLY ASKED QUESTIONS

DUPIXENT is indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype.1

Limitations of Use: DUPIXENT is not indicated for the relief of acute bronchospasm.

Patients enrolled in the BOREAS and NOTUS trials were required to have the following baseline characteristics1,3,4:

  • Current or former tobacco smokers who had a smoking history of at least 10 pack-years
  • Aged 40 to 85 years at time of screeningb
  • Had physician-diagnosed COPD for at least 12 months
  • Had a post-bronchodilator ratio of the forced expiratory volume in 1 second (FEV1) to the forced vital capacity of less than 0.70 and a post-bronchodilator FEV1 of 30% to 70% of the predicted normal value
  • Received a dyspnea score of grade 2 or higher on the Medical Research Council dyspnea scale (scores range from 1 to 5, with higher scores indicating more severe dyspnea)
  • Were receiving background triple inhaler therapy (LAMA+LABA+ICS) for at least 3 months and a stable dose of this therapy for at least 1 montha
  • Displayed signs or symptoms of chronic bronchitis for at least 3 months during the year before screening
  • Had an absolute blood eosinophil count of at least 300 cells/μL at the screening visit
  • Experienced at least two moderate exacerbations or at least one severe exacerbation within the previous year; at least one of the moderate exacerbations must have resulted in the use of systemic glucocorticoids; and at least one exacerbation must have occurred while the patient was receiving triple inhaled therapya
  • Had no history of asthma

aOr double inhaled therapy (LAMA+LABA) if an ICS was contraindicated.

bBOREAS Trial aged 40 to 80 years at time of screening.

COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroid; LABA, long-acting beta agonist; LAMA, long-acting muscarinic antagonist.

see THE FULL
study designs